Following the footprint of porphyrin-mediated photodynamic therapy (PDT), paramagnetic metalloporphyrins were originated as tumor seeking contrast agents (CAs) for magnetic resonance imaging (MRI). However, serial research has disproved their tumor selectivity, identified nonviable tissues as their real targets, and eventually elicited new applications in myocardial infarction delineation, tissue viability evaluation, ablation therapy assessment, as well as first pass or dynamic perfusion MRI, multi-organ contrast enhancement (CE), atherosclerotic plaque imaging and stem cell labeling or tracking. Furthermore, nonporphyrin analogues have been developed to reduce porphyrin related toxicities. These porphyrin and nonporphyrin compounds have been termed as necrosis-avid contrast agents (NACAs) to denote their major discovered affinity. The present review aims to document the evolving research in this particular field, to discuss possible mechanisms, to promote further preclinical and clinical development of this unique and promising class of MRI CAs, and to implicate a novel stroma targeting strategy for diagnosis and treatment of malignant and benign disorders.
INTRODUCTION: DEMANDS FOR SPECIFIC MR CONTRAST AGENTS
Despite the fact that the native tissue contrast can be exploited by magnetic resonance imaging (MRI) to a much greater extent than by any other imaging techniques, there still exists significant signal overlap between diseased and normal tissues. Thus, a need for contrast agents (CAs) to aid lesion detection and characterization was recognized soon after the emergence of MRI. This is evidenced by current widespread applications of gadolinium (Gd) based nonspecific CAs such as Magnevist® (Gd-DTPA) for contrast enhancement (CE) of MRI in daily clinical practice due to their immediate availability, powerful contrast efficacy and excellent safety in patients without severe renal dysfunction [1] [2] [3] [4] .
However, these CAs are characterized with nonspecific distribution in extracellular fluid (ECF) space, simple washin and washout kinetics, sole pathway of renal excretion, and, hence, a lack of real specificity for depicting certain tissue, organ and disease. These intrinsic features have inevitably limited the diagnostic capacity of contrast-enhanced MRI in both clinical and experimental settings. Therefore, there have been continuing efforts for searching more specific CAs that can offer imaging diagnoses with the accuracy approaching that otherwise only achievable with biopsy or histopathology. For instance in detection and characterization of liver tumors, many strategies have been attempted as illustrated in the schemes of Fig. (1) .
Solitary nodules in the liver are often indiscernible on precontrast MRI (Fig. 1A) . The signal intensities of the liver and tumor are both increased after intravenous injection of ECF or blood pool CAs (Fig. 1B) . Whether the contrast between the tumor and liver can be enhanced depends on the However, exceptions do exist due to overlapping between normal and tumor tissues in these aspects. High targetspecificity can be reached by using antibodies (Fig. 1E) , which though have not yet been realized in MRI CAs for in vivo applications due to many theoretical and technological constrains.
Following the footprint of porphyrin derivatives used in cancer photodynamic therapy (PDT), paramagnetic metalloporphyrins were introduced originally as another type of tumor specific CAs for enhanced sensitivity and specificity in MRI diagnosis of malignancies (Fig. 1E) . It is the continuing research on this particular topic that leads to the multiepisode story narrated in this comprehensive review article.
In the field of cardiac MRI, on the other hand, there has been considerable consensus regarding ECF CAs as viability markers with "necrosis-specific" property for delineation of myocardial infarction (MI) using delayed phase contrast enhanced MRI [1] [2] [3] [4] . However, inaccuracy, uncertainty, and multifactorial dependency have also been evidenced [6] [7] [8] [9] [10] [11] . In particular, these CAs are still incapable of making explicit distinctions between reversible and irreversible myocardial insults, between acute and chronic MI, and between ischemic and inflammatory lesions [12] . It was speculated that "the real myocardial infarct size could have been estimated more appropriately using Gd-DTPA with DE imaging 2-3 hr postinjection" [13] , which failed to be supported by a more recent study [11] . Such imperfect competence of ECF CAs satisfies some of the present clinical needs, but will hardly meet ever-raising requirements for healthcare and match ever-advancing pace in instrumental technologies. In this context, a novel type of CAs namely necrosis-avid contrast agents or NACAs with higher specificity on tissue viability has been discovered during preclinical investigations on metalloporphyrins as MRI CAs [14] .
This review is aimed to uncover the link between the two seemingly irrelevant issues, i.e., malignant tumors and myocardial infarction, to document the evolving research in this particular field, to discuss possible mechanisms, and to promote further preclinical and clinical development of this unique and promising class of CAs.
PORPHYRINS AND METALLOPORPHYRINS: KEY LIFE MOLECULES
Porphyrins exist ubiquitously in plants and animals as key functional life molecules. Their basic structure is an aromatic macroheterocycle formed by 4 pyrrole (a fivemembered organic ring each containing a nitrogen) subunits linked through 4 methine bridges (=CH-) with a central binding site available for metal complexation ( Fig. 2A) . Conjugation of the extensive alternating double and single bonds makes it chromatic, hence called porphyrin, a name from the Greek word for purple. Porphyrins coordinate readily with metals in the central cavity by the 4 inward-facing nitrogen atoms, resulting in metalloporphyrins with various important biological properties. For instance, iron-containing porphyrins are called hemes that form functional hemoproteins such as hemoglobin and myoglobin for oxygen transport and storage, and cytochromes for catalyzing intracellular biochemical processes. Similar compounds are chlorophylls that hold a central magnesium ion and function as the photosynthetic apparatus of plants, and bacteria-produced vitamin B-12 that accommodates a cobalt ion and proves vital for cell divisions and nerve cell maintenance.
PORPHYRIN DERIVATIVES: APPLICATIONS IN CANCER THERAPY AND DETECTION
As one of the most important biomedical applications, porphyrin derivatives have been studied over half-century for the diagnosis and treatment of malignant tumors [15] [16] [17] [18] . Selective tumoral uptake, photosensitizing effect and inherent fluorescence are believed to be the three major underlying properties, the first two are engaged in porphyrinmediated cancer PDT [15] [16] [17] [18] and the latter can be usable for optical imaging to detect lesions [19] .
The cancer PDT involves the administration of a photosensitizer such as photofrin II, a derivative of hematoporphyrin (Fig. 2B) via acid catalyzed acetylation, followed by selective illumination of the target tissue with the light of certain wavelength (400-760 nm). The light excites photosensitizing molecules and triggers a series of molecular energy transfers. With the presence of molecular oxygen, a highly reactive and cytotoxic species called singlet oxygen is generated, which causes cell death [18] . Despite tremendous experimental and clinical research activities, the anticancer outcomes vary in literature [20] and the endeavors still keep on for upholding PDT into a mainstream therapy in clinical oncology [21] or redirecting PDT agents into other anticancer applications such as radiotherapy [22] . Although focusing on CAs, this chapter may also shed clues on certain fatal weaknesses encountered by the PDT and the alike in oncology.
The intriguing "tumor-localization" nature of porphyrins has fueled enthusiasms also to develop porphyrin-based diagnostic pharmaceuticals for different imaging modalities [23] . Over decades, porphyrins have been investigated as fluorescent markers [19, 24] or radioactive tracers [25] for tumor detection with encouraging results claimed.
PARAMAGNETIC METALLOPORPHYRINS: PO-TENTIAL TUMOR-SEEKING MR CONTRAST AGENTS
However, it was not until the emergence of MRI later in the last century that paramagnetic metalloporphyrins were developed as tumor-seeking MR CAs, which were intended to utilize the tumoral "preferential uptake" property of porphyrins and to take the versatile advantages of MRI [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . A great variety of such CAs, generally with molecular weights under 2k Da, were produced from many centers worldwide, and in vivo imaging studies on different animal species demonstrated that intravenous or intraperitoneal administration of metalloporphyrins enabled a persistent "tumor-specific" CE on MRI [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
Metalloporphyrin CAs are synthesized by chelation of paramagnetic transition metal ions such as manganese (Mn +2 ) and Gd +3 , which have a number of unpaired electron spins in the outer shells of the electron orbit with relatively long electron-spin relaxation time, hence capable of MRI CE. But these CAs differ largely in complex structures as shown by molecular schemes (Fig. 2) . For instance, Mntetraphenylporphyrin (Mn-TPP) and bis-Gd-DTPA-mesoporphyrin (Gd-MP, or later named Gadophrin-2) are unequal molar agents in respect to their metal contents. In the Mn-TPP molecule, only one Mn +2 ion is chelated at the center of the tetraphenylporphyrin ring (Fig. 2C) . However, in Gadophrin-2 (two Gd elements per molecule) or Gd-MP, the central binding site in the cyclic tetrapyrrole ring remains free while two Gd-DTPA moieties are covalently linked to mesoporphyrin as side chains, i.e. two Gd +3 ions per complex (Fig. 2D) . More recently this CA has been modified into Gadophrin-3 (three metal elements per molecule) by inserting a copper at the porphyrin core for improved stability and safety [38] [39] [40] (Fig. 2E) , which somewhat resembles the copper-centered porphyrin found in shellfish with greencolored blood. The physicochemical and pharmacological properties of both Gadophrin-2 and Gadophrin-3 are described comparable [38] [39] [40] . In addition, some porphyrin compounds, Mn-methylpyrroporphyrin-gadopentetate dimeglumine (Mn-MPP-Gd-DTPA) for instance, combine both core and side chelation forms to improve proton relaxation efficacy [33, 37] .
The Gd +3 ion possessing 7 unpaired electron spins is known to be more paramagnetic than Mn +2 of 5 unpaired spins for use in MRI CAs. The reason for the different metal chelation site at the porphyrins is that, unlike the adequately 
N o t F o r D i s t r i b u t i o n
sized Mn +2 , Gd +3 is too large to be accommodated in the macrocyclic center of ordinary porphyrins, hence complex instability. In order to overcome this drawback, a new class of "expanded" porphyrins including texaphyrins have been synthesized [35, [41] [42] [43] . These compounds contain 5 (instead of 4) N atoms in the ring and possess a central chelating cavity 20% larger than that of ordinary porphyrins, which allows them to form stable complexes with larger trivalent lanthanide metals including Gd +3 [35, [41] [42] [43] (Fig. 2F) .
PRECLINICAL STUDIES: INVESTIGATING TU-MOR-SELECTIVITY OF PORPHYRIN CAS
The key issue in therapeutic and diagnostic applications of porphyrins and analogues rests on the generally believed the "selective" localization in malignant tumors as concluded by previous studies . In the early 1990s, in order to screen a number of metalloporphyrins including Mn-TPP and Gadophrin-2 or Gd-MP for any expected tumorspecificity [33, 37] , careful research was conducted using well established animal models of primary (hepatocellular carcinoma or HCC) and secondary liver tumors with a full spectrum of cellular differentiation [44] . The ECF CA Gd-DTPA was also used as a nonspecific control for intraindividual comparisons in the same animals. Serial MRI was performed up to 48h postcontrast. The meticulous MRImicroangiography-histology matching technique allowed the "zoom-in" observations of different intratumoral components responsible for particular types of CE as exemplified in Fig. (3) [45, 46] . With these methodologies dissimilar to those in all other studies , it was found that the previously reported "specific" tumoral CE could be exclusively attributed to nonviable components (typically necrosis), whereas viable tumor tissues were only nonspecifically enhanced mainly at the early postcontrast phase (Fig. 3) [45, 46] . In other words, this study could not confirm any preferential accumulation of the porphyrins in both primary and implanted hepatomas as long as the tumors were composed of pure viable cells. At early phase, similar to Gd-DTPA, both Gadophrin-2 and Mn-TPP enhanced viable tumor and liver parenchyma simultaneously and the tumor-to-liver contrast was augmented only in some hypervascular tumors (Fig. 3B,B' ). The degree of CE and the rate of signal decay in most of the differentiated HCCs were comparable to those of normal organs such as the liver, spleen and kidney, suggesting similar biologic processes between benign and malignant cells towards porphyrins [45] . At delayed phase of a few hours to a few days, a sustained CE, which is a common finding among other "tumor specific" metalloporphyrins [41] [42] [43] , could be related only to those nonviable intratumoral components such as necrosis, thrombosis and cystic secretion [45] (Fig.  3C' ). These components were also enhanced with Gd-DTPA Fig. (3) . Intraindividual comparison between Gd-DTPA and Gadophrin-2 in a Rat with chemically induced undifferentiated hepatocellular carcinoma. A: On precontrast T1-weighted MRI, the tumor (arrow) appears hypointense; B: Ten minutes after intravenous injection of Gd-DTPA at 0.3 mmol/kg, the tumor (arrow) is strongly enhanced mainly at the periphery leaving a central unenhanced area (small arrow); C: Forty minutes postcontrast, the tumor (arrow) remains enhanced by this high dose while the central unenhanced area (small arrow) is gradually filled due to diffusion of the CA; A': Next day, the Gd-DTPA is completely washed out from the tumor (arrow); B': Forty minutes after intravenous injection of Gadophrin-2 at 0.05 mmol/kg, the tumor (arrow) is strongly enhanced mainly at the periphery leaving a central unenhanced area (small arrow), which is larger compared with Gd-DTPA at the same postcontrast point (Fig. 3C ); C': Two days (48h) postcontrast, while the signal intensity of peripheral tumor (arrow) and elsewhere returns to almost precontrast level, the central area (small arrow) remains enhanced; D: Macroscopy reveals the tumor (arrow) as a heterogeneous mass with central pale areas (small arrow) simulating the structure shown on MRI with the rectangular frame indicating where microscopy is focused; E: HE stained photomicrograph ( 50 original magnification) exposes that the central area showing sustained CE with Gadophrin-2 actually corresponds to necrotic core with attached thrombosis in the intratumoral vascular lake, proving the strong avidity of Gadophrin-2 to nonviable tissue debris. T and N denote viable tumor tissues and necrosis respectively.
by progressive diffusion within one hour postcontrast ( Fig.  3A-C) , which however never persisted to a more delayed phase (Fig. 3A' ), i.e. a rapid nonspecific "wash-in and washout". Because of their different molecular sizes, the uptake by diffusion in nonviable tissues was usually slower with Mn-TPP and Gadophrin-2 than with Gd-DTPA [45] . But once getting inside, porphyrin CAs stayed there for a much longer period and caused a persistent CE over days ( Fig.  3C') , suggesting a strong affinity (or binding) to certain denatured tissue components or cellular debris (Fig. 3D,E) . These observations are just opposite to the assumption raised by an earlier study on similar CAs [33, 37] and against the consensus on the tumor selectivity of porphyrins [41] [42] [43] .
To verify the above controversial findings and to convince the believers of porphyrin-tumor selectivity, an experiment involving more metalloporphyrins including Mn-MPP-Gd-DTPA, Mn-tetra(4-sulfonatophenyl)porphyrin (Mn TPPS4) in addition to Gadophrin-2 and Mn-TPP was conducted in animals with various induced "benign" necroses [46] . Unlike nonspecific control Gd-DTPA, all 4 tested metalloporphyrins were able to induce a strong and sustained CE in all types of necrosis, a pharmacokinetic pattern identical to what have been reported for porphyrins in malignant tumors, i.e. progressive accumulation with a peak uptake at 24 hours. Moreover, this necrosis selectivity could be proven by the measured metal contents being multi-folds higher in necrotic than in normal tissues. Thus without any exception the so called "tumor localizing" phenomenon could be reproduced but only in these nontumoral necrotic lesions regardless of their origin and location [46] (Fig. 4) .
PORPHYRIN TUMOR-SELECTIVITY: A MATTER OF MISTARGETING
These studies explicitly indicate that the identified nonviable tissues should now be regarded as a real common target for many porphyrins and their derivatives, especially those previously defined as tumor specific agents, whereas other intact organs and tissues including viable tumors only take up nonspecifically the porphyrins as certain life molecules at a much lower level [9, 14, [45] [46] [47] . Indeed, it would be very much unlikely that both benign necroses and viable malignancies share identical biological behaviors in terms of porphyrin accumulation and retention [9, 14, [45] [46] [47] . But, how come the porphyrin-tumor selectivity was initiated? A number of arguments can be raised for the following reasoning. 1) Historically, by reviewing the early literature [48, 49] , this concept seems to be originated from misinterpretation of tumoral fluorescence phenomenon, i.e. a matter of which came first, the chicken or the egg. The early investigators found a close relation between intratumoral necrosis and (whether endogenous or exogenous) porphyrins. However, they voluntarily attributed such necrosis as a consequence secondary to the tumoricidal effect of porphyrin-induced phototoxicity, but ignored the possibility that it was the preexisting intratumoral necrosis that caused preferential accumulation of porphyrins.
2) Experimentally, unlike the studies of Ni et al. where tumors of higher cellular differentiation without any intratumoral necrosis were included [14, [45] [46] [47] , almost all previous studies with porphyrin-tumor specificity conclusions exclusively used allograft or xenograft implantation of undifferen- 
N o t F o r D i s t r i b u t i o n
tiated tumor lines that are extremely malignant, aggressive and of high tendency to develop spontaneous necrosis resulting from a mismatch between rapid growth and short nutrition supplies. This explains the higher rate of "positive" findings of porphyrin tumor accumulation in the previous reports [41] [42] [43] , although such "tumor-specific" uptake or CE often appeared inhomogeneous [27] [28] [29] [30] [31] [32] [33] [34] [35] .
3) Methodologically, without the precise and detailed morphological correlations between imaging and histology as shown in the studies of Ni et al. [45, 46] (Fig. 3) , those studies failed to discriminate the histological natures of intratumoral compartments responsible for different CE features [41] [42] [43] . Thus, the overall tumoral CE in the entire tumor quantified on MRI or the content of the agent determined after sampling the global tumor mass was taken for granted as proofs of porphyrin-tumor specificity [27] [28] [29] [30] [31] [32] [33] [34] [35] [41] [42] [43] 50] . Another methodological cause is that in those studies tumors were implanted either at the flank [27] [28] [29] [30] [31] [32] [33] [34] [35] [41] [42] [43] or in the brain [51] with the adjacent normal muscle or brain tissues used as controls, both of which are known to hardly retain any CAs, hence always a high contrast ratio between the tumor and the surroundings, which can be misleading. 4) Consequently, the studies of Ni et al. defined the two distinct metalloporphyrin-induced CE patterns, i.e. the early occurring and gradually fading nonspecific CE in viable tissues (whether normal or malignant) versus the progressively occurring and long-lasting specific CE in nonviable tissues (typically necrotic) [14, 45, 46] . Whereas other porphyrin studies [16, 20, [52] [53] [54] often revealed inconsistent results in terms of porphyrin-tumor selectivity, most likely due to the variable amounts of necrotic tissues in their studied tumoral subjects. Normally the higher proportion of nonviable tissues existed in the tumor, the stronger "tumor specific" CE or uptake of porphyrins was found. This also explains why the preferential porphyrin uptake could not be reproduced by invitro studies using cell culture, where dead cells need to be constantly excluded from the media [55] . Therefore, both justified rationale and adequate methods prove essential for drawing concrete conclusions about the porphyrin targetability [45] . Otherwise, necrosis-specific CE and tumoral nonspecific CE could be frequently confused or admixed if the experiments are improperly designed and conducted [51, 56, 57] .
RESEARCH INSPIRATIONS: TIME TO RECON-SIDER OUR CONCEPTS
Consequently, the current concept underlying the systemic use of porphyrins in cancer for therapeutic and diagnostic purposes should be reconsidered. However, it seems that considerable majority investigators still favor the "porphyrin-tumor selectivity" concept, and research activities are continuously carried out with new hypotheses constantly proposed [18, 53, 58] . Clinical trials are claimed to take the advantage of this property of tumor selectivity, yet the designs appeared somewhat delusive.
For instance, the patients with brain tumors were particularly recruited as the only type of subjects for such a FDA approved clinical trial [59] . But, a lack of real tumor selectivity was thereby masked, because anyhow the lesions would be "selectively" enhanced on MRI with whatever CAs as a result of blood-brain barrier (BBB) breakdown at the intracranial malignances in this group of patients. Surely the claimed tumor selectivity will never show up if the same agent would be tested in tumors located elsewhere as demonstrated in some of the more recent PDT trials [20, 50] .
In another case, based on the properties of so called selective tumor localization and high electron affinity, gadolinium (III) texaphyrin (Gd-tex2+) or motexafin gadolinium (MGd) as a photosensitizer or radiosensitizer detectable with MRI has been intensively studied for cancer PDT or radiotherapy in laboratories and clinical trials [43, 58] , despite the generally disappointing results and controversies about the study reproducibility [60] . It would not be surprising that all these profoundly financed but inconsequential projects could have been avoided if the earlier precautions have been well taken [45] [46] [47] .
Actually, in some other cancer PDT studies, absence of preferential localization of porphyrin agents in subcutaneous implants of hepatoma, liver metastasis, and spontaneous mammary tumor was also documented [52, [61] [62] [63] . Furthermore, the effect of PDT was found much better when the tumor was illuminated 30 min than 6h after photosensitizer administration [64] . This suggests that the vascular destruction during early drug perfusion is much more crucial than the rationale applied in traditional PDT that relies on tumoral drug accumulation over time; and such accumulation, if any, is actually located in the nonviable parts of tumor including necrosis and interstitial stroma [65] in contrast to the minimal uptake in viable tumor cells, hence negligible tumoricidal effect [64] . Thus, the tumor selectivity in PDT here was apparently realized mainly by light illumination focused on tumor spot and had nothing to do with tumor selectivity of the drug, just like the photochemical approaches used to induce animal models of focal cerebral infarction or stroke [66] . All other theories such as targeting LDL-receptor do not seem to prove viable. The direct effects of PDT are very limited with less than 2 logs of neoplastic cells being killed, far short of 6-8 logs needed for tumor cure [53] . This is in line with our findings that the true targets of NACA-like chemicals including PDT photosensitizers are stroma matrices instead of viable tumor cells [14, [45] [46] [47] . All the research outcomes may have collectively impacted on the current trend of PDT for changing from systemic to topical use in cancer treatment, and from malignant to benign disorders in indicated applications [21] .
The next important issue is how to avoid similar mistargeting errors in the future for the sake of properly handling the limited socioeconomic resources of our planet. One simple and effective way proposed here is to verify any existing and newly emerging "tumor-targeting" porphyrins, their derivatives and functional analogues by testing them in vivo with the well defined animal models of necrosis, which ensure ample access for the agent being subsequently interact with the lesions, and sufficient drainage for the agent being subjected to natural washout [46, 67] . If a typical selective retention with a multi-fold necrosis-over-normal ratio occurs, most probably the tested agent would not be a desired localizer for viable tumors but a new NACA. Recently, this method has been successfully applied for disqualifying the
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claimed "tumorotropic" feature of a well-known PDT photosensitizer [14, 68] .
NECROSIS-SPECIFIC MARKERS: A NEED HIGH-LIGHTED BY ONGOING RESEARCH
Over the past couple of decades, necrosis imaging has been one of the focused interests particularly in nuclear scintigraphy [69] [70] [71] , which has also affected the research in MRI. Phosphonate modified Gd-DTPA complexes could produce a strong and prolonged CE in diffuse and occlusive MI due to their affinity for calcium-rich tissues and subsequent formation of insoluble calcium phosphate precipitates in the damaged myocardium. However, they may cause calcium-homeostasis disorder and consequently impair ventricular contractility [72] . Besides, studies with technetium99m pyrophosphate, a scintigraphic analogue of this type, showed a lack of specificity between ischemic and necrotic myocardium [73] leading to a significant overestimation of the infarct size [74] . On the other hand, antimyosin-antibody labeled magnetopharmaceuticals represent an appealing approach. However, the unaffordable costs, possible immunogenic side-effects, insufficient expression of antigens over limited MRI sensitivity to the currently available relaxation enhancers, and complexity in preparation and handling of the antibody-agents all challenge their ultimate clinical utility [75] . Of greater interest, the afore-mentioned research activities have dramatically converted those paramagnetic metalloporphyrins from tumor-seeking CAs into a new type of small molecular magnetic markers for necrosis [14, 47] .
NECROSIS-AVID CONTRAST AGENTS (NACAS): PORPHYRIN AND NONPORPHYRIN SPE-CIES
Unfortunately, these porphyrin-based CAs can no longer be considered as true tumor-specific markers, but their superb necrosis targetability has elicited novel and even more exciting utilities for MRI visualization of acute myocardial infarction [9, 14, [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] ] and brain infarction [87] . Being able to induce strong, selective and stable CE is an important criterion for consideration of tissue or disease specific MRI CAs. With regard to the quality of CE in necrosis, the tested porphyrin CAs perfectly meet this criterion. To distinguish from other antibody or receptor mediated tissue specific CAs that feature apparently different mechanisms of targetability, we propose to nominate these metalloporphyrin compounds and later developed functional analogues of nonporphyrin species as "Necrosis-Avid Contrast Agents" or NACAs because of the exhibited extraordinary avidity to necrotic and/or infarcted tissues as their main targets [9, 14, [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] .
Following a few years' experience of peer-suspicion and resistance understood as various unspeakable manifestations [14] , eventually the potent effects of Gadophrin-2 for labeling necrotic myocardium on MRI have been widely recognized after multi-institutional reproducibility studies [7, 14, [88] [89] [90] [91] [92] [93] [94] . In addition to intravenous doses of porphyrinNACAs at 0.05-0.1 mmol/kg for cardiac MRI to visualize acute MI with an extended imaging window over 3-48 h [7, [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [88] [89] [90] [91] [92] [93] [94] , intracoronary delivery of Gadophrin-2 at a tiny dose of 0.005 mmol/kg in combination with the percutaneous transcatheter coronary angioplasty procedures could function as a diagnostic adjuvant for myocardial viability determination and therapeutic assessment after these routine cardiac interventions [9, 14, 76, 86, 95] . This approach was rated by the French specialists as one of the best cardiac imaging techniques in 2002 [96] . By contrast, improper methodologies may often lead to invalid study conclusions about porphyrin-based NACAs for their applications in experimental MI, causing either the undervalued capacity for enhancing the occlusive MI [97] or the inaccurate delineation of MI when comparing with ECF CAs [38] , as indicated in the more recent literature [39, 81, 98] . Other than spontaneous necroses such as acute MI, porphyrin-based NACAs could also label tissue death after interstitial thermal therapies including radiofrequency ablation (RFA) of solid tumors [99, 100] .
To date, triphenyltetrazolium chloride (TTC) staining has been used as the only gold standard for macroscopic identification and quantification of acute MI. Yet, it is merely a post-mortem technique and hardly applicable in clinic. Studies have revealed that after intravenous and intracoronary NACA-injections, the specifically enhanced area on cardiac MRI corresponds exactly to TTC negatively stained region, resulting in the same accuracy for MI delineation [7, 9, 11, [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [88] [89] [90] [91] [92] [93] [94] . The measured local Gd concentration is often tens of times higher in infarcted over normal myocardium, surpassing any other reported infarct-targeting reagents. Experimentally, Gadophrin-2 enhanced MRI has been used as an inverse surrogate of TTC histochemical staining or an in vivo viability gold standard for evaluation of medicinal myocardial protection [94, 101, 102] and interventional RFA [99, 100] .
Novel applications of porphyrin-based NACAs in the preclinical experiments on cardiovascular, oncological and even molecular imaging topics are still emerging from different research centers [41, [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] . Except for slight discoloration that faded considerably over 24 hours, during animal experiments no detectable side effects were reported with porphyrin agents at a dose range of 0.05-0.1 mmol/kg [7, [38] [39] [40] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [87] [88] [89] [90] [91] [92] [93] [94] 97, 99, 100] . Unfortunately, despite optimistic expectations [104] , further commercial development of these chromatic porphyrin complexes has been abandoned by the industry, most likely due to predicted unsatisfactory clinical tolerance and adverse effects upon the unalterable natures of these dark pigments (Fig. 5A) [14] .
To overcome the discoloration, phototoxicity and other unwanted-effects related to porphyrins, strenuous efforts have been made to search more effective, less toxic and less colored alternatives. First, to verify whether the tetrapyrrole rings of all porphyrins is essential or not for targeting necrosis, more porphyrin CAs were examined and it turned out that 4 out of 9 metalloporphyrins did not show necrosis affinity [106] . Such unequal performances among different porphyrin CAs, also occurring in cancer PDT [15, 16, 18] and tumor imaging [33] , suggest that the tetrapyrrole ring should not be a common structural requirement for the observed targetability. Furthermore, other Gd-chelates conjugated to either open tetrapyrrole chains such as bilirubin and biliverdin or smaller segments such as mono-, bis-and tripyrrole derivatives also failed to reveal a necrosis-specificity [79] . These findings not only disprove any inevitable linkage between porphyrin-like structures and the affinity to necro-
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sis, but also implicate the possibility to generate some totally different nonporphyrin complexes. Thereby these new generations of NACAs may become more effective, less colored or even colorless, and completely deprived of all adverse effects associated with porphyrins. Following a rational roadmap with certain technical breakthroughs, a few promising leading compounds have been successfully synthesized, such as the yellowish bis-Gd-DTPA-pamoic acid (ECIII-60) and the colorless bis-Gd-DTPA-bisindole (ECIV-7) [14, 79, 107, 108] (Fig. 5) . The former (Fig. 6A) is derived from pamoic acid, which is a common matrix for pharmaceutical preparations [109] ; and the later indole derivative (Fig. 6B) partially simulates catabolic metabolites of organisms [110] , with both being presumably more biocompatible than those manufactured materials [111] . These two nonporphyrin NACAs have exhibited even higher necrosis avidity in comparison with those porphyrin NACAs [11, 14, 112] .
Besides the above defined porphyrin and nonporphyrin NACAs, there are a few newly emerging CAs originally developed for diverse utilities, but also would likely serve as potent NACAs (Table 1) . For examples, Gd-(ABE-DTTA) is a long lifetime water-soluble lipophilic myocardium-specific CA dedicated for cardiac MRI [113] , but later found to cause persistent CE in MI and thus redefined as infarct-avid persistent contrast agent (PCA) [114] ; EP-1873 and EP-2104R are introduced as fibrin-binding "molecular" MRI CAs used in animal models and clinical trials to visualize blood clots, but also showing strong affinity to necrotic components of the atherosclerotic plaques [115, 116] ; P947 is gadoliniumlabeled short peptide ligand presumably avid for atherosclerosis-associated matrix metalloproteinases (MMPs) and allows MR molecular imaging of atherosclerotic plaque [117] ; and Gadofluorine M, originally used as a lymphotropic or 
blood pool CA, has also been classified as a NACA [95, 118] . More recently, gadolinium-chelated polyglutamic acids (L-PG-DTPA-Gd and D-PG-DTPA-Gd) with the heavy molecular weights around 100k Da were introduced for noninvasive MRI characterization of treatment-induced necrosis [119] . All these CAs would likely fall into the welldefined category of NACAs (Table 1) , especially if after being validated by the above recommended testing system [46, 67] . This phenomenon of functional similarity versus structural diversity with NACAs and their analogues has been addressed in a recent review article [14] . So far, all NACAs as MR CAs are T1 relaxation enhancers and show the targets with bright or positive signals typically at a 1.5T clinical magnet. However, the target-over-normal contrast ratio (CR) may differ significantly upon the exact T1-weighted MR acquisition sequence applied and typically the CR with a potent NACA should be above 1.5 over 24 hours. In general, conventional T1-w spin echo (SE) sequence may provide a higher CR in comparison with turbo spin echo (TSE) sequence, whereas T1-w inversion recovery (IR) sequence may generate the highest CR depending on an adequate inversion time.
CLINICAL POTENTIALS OF NACAS: SPECIFIC AND NONSPECIFIC APPLICATIONS
All studied porphyrin or nonporphyrin NACAs allowed differential diagnoses between reversible ischemic injury and irreversible infarct, acute and healing MI, and occlusive and reperfused MI (Fig. 7) [7, 9, 11, 14, 38, 39, 104] . Even negative findings after CE with NACAs help to reliably exclude the presence of necrosis and to reaffirm tissue viability, which would also be of high significance for differential diagnoses in clinical cardiology [76, 81, 95] . Local high concentrations of NACAs enabled both T1 and T2 CE in reperfused MI at relevant MRI sequences, suggesting their extraordinary bifacial MR enhancing capacities [14] . In a proposed comprehensive "one-stop-shop" cardiac MR package for myocardial viability assessment, the NACA serves as the only key factor that can provide a clear-cut distinction between viable and necrotic myocardium [76] . This proves crucial for stratification of patients with acute coronary syndrome and for subsequent therapeutic planning in potential clinical applications.
Recently another urgent need of NACAs for therapeutic assessment has been emphasized, which is to differentiate Note: MW: molecular weight; * proven or to be proven in the acute reperfused infarction models [11, 46, 67, 114] ; NA: information not available from literature.
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residual tumor tissue and periablational benign reactive tissues after minimally invasive ablations of malignant tumors such as RFA [14, 67, 112, 120, 121] . While impossible to achieve with nonspecific CAs including macromolecular blood pool CAs or commercial ECF CAs [13, [121] [122] [123] , the use of NACAs in this regard [14, 112, 120, 121] may fundamentally solve the problems posed by two recent articles [122, 123] . Thus, functioning as a virtual biopsy technique, the resultant NACA-enhanced MRI would provide unconditional and unambiguous visual outcomes for physicians to make early differential diagnosis and therapeutic adjustment [14, 112, 120, 121, 124, 125] , hence higher cure rate for these anticancer therapies. Studies with a new nonporphyrin NACA has demonstrated that with the nonspecific liver CE gradually diminishing from minutes to hours postcontrast, a specific rim or "O" type CE around the RFA lesion indicates a complete tumor ablation, whereas an incomplete rim or "C" type CE with moderately discernible contrast at the residual viable tumor suggests an incomplete tumor ablation [14, 112, 120, 121, 124, 125] . Therefore, NACAs seem advantageous over any other existing contrast agents for this particular application due to their characteristic CE and optimal phase in relation to the cell type (malignant or benign) and tissue viability (living or necrotic) [14, 112, 120, 121, 124, 125] . The NACAs will also prove their great potentials in other oncological applications including response calibrations in chemotherapy and radiotherapy [119] .
Interestingly, it has been reported that porphyrins and an expanded porphyrin target atherosclerotic plaques due to their preferential accumulation in the nonviable matrices with or without uptake by macrophages [35, [126] [127] [128] . Given the functional similarity observed between porphyrin and nonporphyrin NACAs, further studies may reveal that plaque-targeting could well be one of the NACAs' targeted applications [76, [115] [116] [117] [118] .
Indeed, both porphyrin and nonporphyrin NACAs exert their necrosis targeting effect only when nonviable tissues exist in the living body. Aside the necrosis-targeting property, NACAs also cover other utilities commonly seen with all existing CAs [1] [2] [3] [4] 6, 129, 130] . For instance, the relatively long plasma half-life due to protein binding facilitates their use as blood pool CAs for MR angiography (Fig. 8) [14] especially of coronary arteries; their amphiphilicity as well Fig. (7) . Nonporphyrin NACA ECIV-7 in a rabbit with acute reperfused myocardial infarction. T1-weighted in vivo long axial (A) and short axial (B) cardiac MRI and postmortem high resolution MRI (C) overnight after intravenous injection of ECIV-7 at 0.05 mmol/kg delineate clearly the infarcted area with involvement of posterior papillary muscle (arrow). TTC histochemical staining (D) matches perfectly the MRI findings.
Fig. (8).
Intraindividual comparison between Gd-DTPA and nonporphyrin NACA ECIV-7 for MR angiography in a rabbit. A: Precontrast, the inferior vena cava and renal vein branches are hypointense (arrow); B: One minute after injection of Gd-DTPA at 0.1 mmol/kg, these vessel branches (arrow) are slightly enhanced in comparison with the strong CE in the kidneys. C: Six minutes postcontrast, the CE in these vessel branches (arrow) virtually disappears. However, after re-injection with ECIV-7 at 0.05 mmol/kg in the same animal, these vessel branches (arrow) remain strongly enhanced over 1 min (A'), 20 min (B') and 70 min (C') respectively, suggesting the blood pool CE property of NACAs.
as hepatobiliary and renal pathways render applications for liver and kidney specific CE [14, 112] . NACA induced strong adrenal CE has also been noticed in animal experiments [14, 80, 120] . More excitingly, the porphyrin NACA gadophrin-2 has been exploited as a bifunctional CA for MR imaging, optical imaging, and fluorescence microscopy in the research for in vitro labeling and in vivo tracking of stem cells [105] . Therefore, with versatile specific and nonspecific capacities, NACAs may serve well as multipurpose MR CAs [14, 76, 80, 95] . A similar example can be found with the commercialized MR CA Gd-BOPTA (MultiHance®) [131] , which is though lack of specific effect of necrosis avidity.
THE MECHANISMS OF NACAS: HYPOTHESES AND EXCLUSIONS
The laureate of 1959 Nobel Prize in Medicine Arthur Kornberg (1918 Kornberg ( -2007 once thus denoted "You cannot prove a mechanism; yet you can only disprove a mechanism", which portrays exactly the current status of the NACAs with respect to their mechanisms of actions. For instance, by performing dedicated tests, Hofmann et al. attributed specific accumulation of Gadophrin-2 to its binding to plasma and interstitial albumin, and to the subsequent trapping in intratumoral necrotic regions [132] . However, this conclusion could not be proven by a few recent studies: one comparing a porphyrin NACA Gadophrin-2 and a strong albuminbinding blood pool CA MP2269 [67] , one analyzing a chemical analogue of a nonporphyrin NACA with strengthened protein binding capacity [133] , and another studying intratumoral uptake of albumin-based macromolecular therapeutic agents in human melanoma xenografts [134] . All these studies suggest that only few albumin-binding agents may possess NACA property, whereas almost all NACAs tend to reversibly bind plasma proteins (typically albumin) to a certain extent. In other words, the necrosis avidity is an outstanding feature beyond generally acknowledged pharmacokinetics of protein-binding mediated drug transportation [14] . Therefore, to nominate a CA with NACA property [95] as "a protein-avid contrast agent" does not seem to be accurate [118] .
Regarding the NACA mechanisms, hypotheses have been raised according to experimental observations [14, 45, 46, 67] , which have partially been supported by ongoing research using a MRI-fluorescence-histology colocalization technique (Fig. 9) . Understandably, targeting of NACAs to necrosis arises in a likely chemotactic fashion as follows [14, 45, 46, 67] .
While circulating in the blood-pool after administration, the NACA molecules (with or without protein binding) approach the necrotic region by perfusion through residual blood vessels (Fig. 9B) , extravasation and interstitial diffusion, whereby reperfused infarction appears more favorable than occlusive infarction for NACA accumulation due to the ampler access [11, 81] .
The disintegrated cell-membrane after autolysis facilitates direct communication of NACAs with the necrotic debris. Following enzymatic denaturation mediated by inflammatory infiltration as the nonspecific body immune reaction towards tissue injury and cell death, certain exposed radicles that are normally hidden inside intact macromolecules of cells or tissues may attract and interact physicochemically with NACA-like chemicals to form strong bonds. This immobilization may benefit the concentration gradient in favor of equilibrium towards a local accumulation especially at the delayed phase when the amount of circulating NACAs has largely decreased. The involvement of ionic bond in the phenomenon of NACAs can be suggested by the fact that most of the NACA-like chemicals are negatively charged. But not all negatively charged chemicals possess NACA properties and covalent bonding or metallic bonding may also complicate to form stronger binding.
Such interactions between chemicals and necrotic debris (typically degraded proteins and/or peptides) are usually indiscernible unless applying discernable labels such as dye, fluorescence, radioactive tracers and magnetic metals (Fig.  9) . In the latter case, further augmentation of relaxivity due to macromolecular interactions may in turn lead to a striking CE of the infarct on T1 weighted MRI [14, 135] . By ex vivo measurement, the T1 and T2 relaxivity of water protons with NACAs are typically close to 10 (mM·s)-1, which doubles that with ECF CAs [7, 45, 77, 83, 94] . However, once accumulated in necrosis, their relaxivity may be further unproportionally increased [14, 46, 83] . Because of local high concentration of Gd resulting from such chemotactic accumulation, T2* susceptibility contrast effect of such T1 CAs can become predominant especially on T2-weighted MRI [14] .
Recent studies suggest that this type of local interaction and retention seems strictly dependent on chemo-structure rather than a simple trapping or sluggish wash-in and washout, because either slight modification or even isomer transformation may drastically switch off the necrosis-targetability of certain NACAs [14, 133, 136] .
In respect to target tissues, the size and site of infarcted areas as well as the presence or absence of postischemic reperfusion determine what kind of NACA induced necrosisspecific CE appears (i.e. patchy or bulky, subendocardial or transmural, and complete or rim-like) and how long the CE may persist [81, 112] . Unlike the "detrapping" process of nonspecific CAs over a few quarters of time [9, 45, 83, [121] [122] [123] , the eventual clearance of NACAs from necrotic foci typically takes a few days after administration and parallels the natural healing process [9, 45, 83] , during which necrotic tissues are progressively infiltrated and phagocytized by inflammatory cells (mainly neutrophils, monocytes or macrophages and fibroblasts) and replaced by granulation tissues (Fig. 9 E-G') . Therefore, the retained NACAs in necrosis are most likely removed together with necrotic materials by phagocytosis. Likewise, secondary macrophage uptake following NACA-necrosis binding may account for the local enrichment as well [14, 119] . This endocytosis with the involvement of migrating and/or residing macrophages implies a new way for targeting stromal cells [14, 119] .
Questions remain as for whether the Gd-complex of NACAs is still stable after being taken up by macrophages and what about the fate and consequence of this small necrosis-binding fraction of NACAs in the human body [14, 67, 76] . These details have to be further elucidated. Alternatively, to substitute the bio-incompatible lanthanide metal element Gd 3+ with the physiological trace metal element Mn 2+ in the complex of NACAs might eliminate the
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concerns about any potential side effects, such as nephrogenic systemic fibrosis (NSF), due to gadolinium body retention [14, 107, 108] .
NECROSIS AVIDITY: A NATURAL PROCESS TO EXPLOIT
Besides the above nominated porphyrin and nonporphyrin NACAs for enhancing MRI (Table 1) , there appears to be a large variety of synthetic or natural, endogenous or exogenous substances, which all seem to share a common necrosis-avidity. These include the synthetic dye Evans blue used for macroscopic intravital staining [137] and its chemical analogues such as Trypan blue (a vital dye for dead cell exclusion in cell culture) and Congo red (a dye and pH indicator); the botanical extract hypericin derived from St. Johns Wort with multiple pharmaceutical utilities [64] [65] [66] 68, 136, [138] [139] [140] [141] [142] , the heme-related cofactor hematoporphyrin for oxygen transportation (Fig. 2B) [15] [16] [17] [18] , the greenish or yellowish bile pigment commonly seen in intrahepatic necrosis of both tumoral or benign lesions even without accompanying cholestasis, Annexin V originally used as apoptosisspecific reagent [143] , fluorescent or MRI detectable markers for amyloid plaques in Alzheimer disease [144] , and many more to be identified. It is known that many of these substances are chromatic and become fluorescent when they bind to some (but not all) proteins or their degraded peptides (http://www.histosearch.com/histonet/Oct98A/Re.EvansBlue otherfluoresc.html). This simulates the high selectivity of NACAs to certain denatured life molecules. They may all firmly bind to necrotic debris including degraded subcellular organelle proteins such as positively charged histone of chromatin [14, 68, [137] [138] [139] , though our recent study indicates that necrosis avid molecules mainly bind cytosolic instead of nucleic substances of the dead cells. However, unless being of inherent color and/or fluorescence, the resultant products can hardly be noticeable prior to being labeled with detectable markers, which forms the base to develop necrosis-avid radiopharmaceuticals [69] [70] [71] [72] [73] [74] 138, 139] and magnetopharmaceuticals [7, 9, 14, [38] [39] [40] 67, [104] [105] [106] [107] 132] . The discernible alterations of NACA-like chemicals may ease the study of mechanisms and biodistribution of this type as exemplified in Fig. 9 . Recently we observed that similar to the denatured cellular substances found in necrotic foci, certain intact stromal proteins of connective tissues such as elastin and fibrin, and collagen to lesser extent, may also share avidity to NACA-like chemicals, although the binding (fluorescent) intensity may differ in individual conditions. These observations suggest that subcellular substances in necrosis (after enzymatic degradation) and certain normal structural proteins expose similar binding sites that are required for the avidity to NACA-like molecules. This and earlier found specific CE in intratumoral thrombus [45] may justify the classi- fication of the fibrin-binding MRI CAs EP-1873 or EP-2104R into the category of NACAs (Table 1) .
Thus, the generally perceived structural diversity versus functional similarity, i.e. the presence of porphyrin versus nonporphyrin, cyclic versus linear, natural versus artificial, internal versus external, small molecular versus macromolecular NACA-like chemicals, supports our hypothesis that the avidity of certain chemicals to necrotic debris and stromal molecules in the living body is an ever existing phenomenon as part of the native wound healing mechanisms, which has not been well recognized but deserves to be wisely exploited for medicinal purposes [14, 68, 133, [136] [137] [138] [139] .
CONCLUDING REMARKS: TOWARDS A STROMA-TARGETING STRATEGY
It is well known that stromal matrices and cells play important roles in both malignant and benign pathological processes such as metastasis and neoangiogenesis, and targeting stroma to modulate the microenvironment has become a new strategy for combating various diseases [145, 146] . However, how to selectively target the affected stroma for further therapeutic interventions still remains a great challenge. As featured by this review, research initiated from cancer PDT has gradually led to the discovery of a natural targeting approach primarily to the stromal matrices through chemotactic affinity and secondarily to stromal cells through phagocytosis (Fig. 9) [147] .
Therefore, besides serving as CAs for various welldefined specific and nonspecific clinical potentials as well as for new molecular and/or cellular imaging applications, the NACA-like chemicals can also be exploited to function as vectors that are tagged with therapeutics and able to target stroma in a natural way, thereby the functions of the stromal cells can be modulated. For instance, by rational pharmaceutical engineering, the neoangiogenesis can thus be either stimulated in regenerative therapies for MI and stroke or inhibited in the treatment of malignancies (Fig. 10) . Further efforts in this direction may not only generate refined NACAs for imaging diagnoses but also promote novel stroma-modulating therapies.
To realize this goal, research gathering cross-disciplinary expertise proves critical. The key steps include understanding the underlying mechanisms of necrosis avidity and identifying the exact local configurations responsible for such strong physicochemical interactions through careful analyses on the structure-function relationship from all available NACA-like substances. Then, it might be possible to create dedicated all-in-one multifunctional agents called diagnotherapeutics by purposely tailoring their chemical structures. Such molecular engineering might render additional NACA targetability onto any known substances including common life molecules such as vitamins, amino acids or peptides, simple carbohydrates, as well as the medicines already in use such as anti-ischemic drugs or thrombolytic agents, antibiotics and antineoplastics. This strategy appears to be more nature-borne and may avoid hazards inherent with excessive artificial manipulations as exemplified to some extent by the development of "intelligent" CAs consisting of totally nonphysiological substances [111, 148] . The latter approaches are simply unrealistic for human applications and would ever remain investigational [111, 148] ; whereas the exploration utilizing natural pathways may form a more operable, biocompatible, economical, ecological and ethical platform for research and development of CAs wherein more constructive interactions between academics and industries are supposed to be necessary and should be encouraged [14] . 
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